Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
Molecular Pharmaceutics|July 25, 2018
Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug ConjugatesZhonghua Pei, Chunjiao Chen, Jinhua Chen, et al.
Bioorganic & Medicinal Chemistry Letters|January 7, 2020
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)Peter S Dragovich, Pragya Adhikari, Robert A Blake, et al.
Chemical Science|April 13, 2022
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptidesNeelie Zacharias, Vladimir N Podust, Kimberly K Kajihara, et al.
Bioconjugate Chemistry|April 11, 2019
Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In VivoDian Su, Jinhua Chen, Ely Cosino, et al.
Bioanalysis|December 23, 2014
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input)Dawn Dufield, Hendrik Neubert, Fabio Garofolo, et al.
Bioanalysis|December 6, 2017
2017 White Paper: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies' inputs)Hendrik Neubert, An Song, Anita Lee, et al.
Bioanalysis|December 14, 2019
2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (Part 2 - Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity)Brian Booth, Lauren Stevenson, Renuka Pillutla, et al.
Pageof 10